Treatments for mild-to-moderate recalcitrant plaque psoriasis: Expected clinical and economic outcomes for first-line and second-line care

Dermatology Online Journal

Volumn 11, Issue 1, 2005, Pages

  Marchetti, Albert ^a   Feldman, Steven R ^a   Kimball, Alexandra Boer ^a   Anderson, Richard Rox ^a   Miller, Laurence H ^a   Martin, John ^a   An, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; DITHRANOL; PSORALEN; STEROID; TAZAROTENE;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EXCIMER LASER; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; MEDICAL LITERATURE; OUTCOMES RESEARCH; PHOTOTHERAPY; PRACTICE GUIDELINE; PSORIASIS VULGARIS;

EID: 21844453371     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Weinstein GD, Gottlieb AB, editors. National Psoriasis Foundation: therapy of moderate to severe psoriasis. Stanford (CT): Haber and Flora, Inc. 1993. p.3.
2. Roenigk HH. Maibach HI. editors. 2nd ed. New York: Marcel Dekker; 1991. P 213 -214
3. Stern RS. Utilization of outpatient care for psoriasis. J Am Acad Dermatol 1996;35:543-545
4. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-860
5. Krueger GG, Bergstresser PR, Lowe NJ, Voorhess JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol 1984; 11:937-947
6. Griffiths CEM, VoorheesJJ. Psoriasis, T-cells and Autoimmunity. J R Soc Med 1996;89:315-319
7. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Textbook of dermatology. 6th ed., Vol. 3. Oxford: Blackwell Scientific Publications; 1998. p.1589-1649
8. De Arruda LHF, De Morales APF. The impact of psoriasis on quality of life. BJD 2001;144(suppl 58): 21-5
9. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796 -802
10. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999;107:595-605
11. Fredriksson T, Lassus A, Salde L. Reproducibility of clinical trials of topical gloucocorticosteriods. Int J Dermatol 1983; 22: 536-539
12. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999;107:595-605
13. Feldman, SR. Psoriasis treatment. Curr Prob Dermatol 1998;10(1):1-40
14. American Academy of Dermatology. Committee on Guidelines of Care, Task Force on Psoriasis. Guidelines of care for psoriasis. J Am Acad Dermatol 1993;28:632-7
15. Koo J. Sequential therapy for psoriasis. NPF Psoriasis Forum 1998;4(2)3
16. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41:S25-28
17. Redbook, 2003
18. Center for Medicare and Medicaid Services, 2003 National Physician Fee Schedule Relative Value File
19. Lebwohl M, Abel E, Zanolli M, Koo J, Drake L. Topical therapy for psoriasis. Int J Dermatol 1995;34: 673-84
20. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501-3
21. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative vehicle-controlled study. J Acad Dermatol 2992;27 (6 pt 1):983-8
22. American Academy of Dermatology. Committee on Guidelines of Care, Task Force on Psoriasis. Guidelines of care for psoriasis. J Am Acad Dermatol 1993;28:632-7
23. Feldman, SR. Psoriasis treatment. Curr Prob Dermatol 1998;10(1):1-40
24. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Freidman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92]
25. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatm of psoriasis. Arch Dermatol 1998;134:57-60
26. Goldfarb MT, Ellis CN, Voorhees JJ. Short-term and long-term considerations in the management of psoriasis with retinoids. Dermatologica 1987;175:100-6.
27. Ellis CN, Swanson NA, Grekin RC, et al. Etretinate therapy causes increases in lipid levels in patients with psoriasis. Arch Dermatol 1982;118:559-62.
28. Ellis CN, Voorhees JJ. Etretinate therapy. J AM ACAD DERMATOL 1987;16:267-91.
29. AAD Draft Consensus Statement on Psoriasis Therapies. Psoriasis Therapies Educational Summit. American Academy of Dermatology. November 2-3, 2002
30. Stern RS. Genital tumors among men with psoriasis exposed to psoralen and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Phototherapy Follow-Up Study. N eng J Med 1990;322:1093-1097 Abstract
31. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study N Eng J Med 1997;336:1041-1045
32. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. The Photochemotherapy Follow-Up Study. Cancer 1994;73:2759-2764 Abstract